SLI in the context of tuberculosis (TB) refers to second-line injectable drugs, specifically amikacin, kanamycin, and capreomycin. These are important medications used to treat drug-resistant forms of TB.
Understanding SLI in TB Treatment
The acronym SLI is important when discussing drug-resistant TB. Here's a breakdown:
- Second-line Drugs: These are medications used when first-line TB drugs are ineffective due to resistance.
- Injectable: These specific second-line drugs are administered through injection.
- Specific Drugs: SLI encompasses:
- Amikacin
- Kanamycin
- Capreomycin
- Pre-Extensively Drug-Resistant TB (Pre-XDR-TB): The reference mentions pre-XDR-TB, which can be associated with resistance to fluoroquinolones or at least one of the SLIs mentioned. In the pre-bedaquiline era, resistance to at least one SLI was classified as pre-XDR-TB (SLI).
SLI Usage and Resistance
| Drug | Classification | Administration |
|---|---|---|
| Amikacin | Second-line Injectable | Injection |
| Kanamycin | Second-line Injectable | Injection |
| Capreomycin | Second-line Injectable | Injection |
- Resistance Development: When TB bacteria develop resistance to SLIs, treating the infection becomes more complicated.
- Treatment Options: Proper identification of resistance is crucial for selecting effective treatment regimens.
- Public Health Implications: Resistance to SLI is a significant public health concern, requiring careful monitoring and strategies to prevent further spread.
Summary
In TB, SLI stands for Second-Line Injectable drugs, and refers to the specific medications amikacin, kanamycin, and capreomycin, crucial in treating drug-resistant forms of tuberculosis. Resistance to these drugs poses significant challenges for TB control.
